

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

MP9956:SFG.GD3synthase-2A-GD2synthase

RRID:Addgene_75013

Type: Plasmid

Proper Citation

RRID:Addgene_75013

Plasmid Information

URL: <http://www.addgene.org/75013>

Proper Citation: RRID:Addgene_75013

Insert Name: murine GD3 synthase

Organism: Mus musculus

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:27030986](#)

Vector Backbone Description: Backbone Marker:Mulligan laboratory; Vector Backbone:SFG; Vector Types:Mammalian Expression, Retroviral, MoMLV retroviral vector; Bacterial Resistance:Ampicillin

Plasmid Name: MP9956:SFG.GD3synthase-2A-GD2synthase

Record Creation Time: 20220422T222456+0000

Record Last Update: 20260815T081942+0000

Ratings and Alerts

No rating or validation information has been found for MP9956:SFG.GD3synthase-2A-GD2synthase.

No alerts have been found for MP9956:SFG.GD3synthase-2A-GD2synthase.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gardam B, et al. (2026) A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors. Clinical & translational immunology, 15(4), e70093.

Gardam B, et al. (2026) Tumors located in the brain impair the frequency and phenotype of dendritic cells in blood and tumor. iScience, 29(3), 115160.

Stip MC, et al. (2023) IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models. Journal for immunotherapy of cancer, 11(7).

Liu X, et al. (2022) Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. Journal for immunotherapy of cancer, 10(4).

Agliardi G, et al. (2021) Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nature communications, 12(1), 444.

Charan M, et al. (2020) GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. International journal of cancer, 146(11), 3184.